サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：パーキンソン病治療薬の世界市場：市場規模 - 年齢層別、薬物クラス別、投与経路別、地域別展望、競合戦略、セグメント別予測（～2032年）
市場調査レポート
商品コード
1159580

パーキンソン病治療薬の世界市場：市場規模 - 年齢層別、薬物クラス別、投与経路別、地域別展望、競合戦略、セグメント別予測（～2032年）

Parkinson's Disease Drugs Market Size- By Age Group, By Drug Class, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 246 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
パーキンソン病治療薬の世界市場：市場規模 - 年齢層別、薬物クラス別、投与経路別、地域別展望、競合戦略、セグメント別予測（～2032年）
出版日: 2022年11月18日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 246 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のパーキンソン病治療薬の市場規模は、2032年までに109億3,000万米ドルに達し、CAGRで6.5％の成長が予測されています。

市場成長を促す重要な要因として、パーキンソン病の患者数の多さと診断率の向上が挙げられます。主要企業によるパーキンソン病治療薬の研究開発投資の増加や、高齢者人口の増加は、産業成長を促進する要因の一つとなっています。

当レポートでは、世界のパーキンソン病治療薬市場について調査し、市場力学、市場変数と見通し、年齢層・ 薬物クラス・投与経路・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

  • 調査範囲
  • 市場セグメント分析

第2章 調査手法

  • 調査データソース
  • 市場規模の推定
  • データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因、抑制要因、機会、課題の分析
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 世界のパーキンソン病治療薬市場におけるCOVID-19の影響

第5章 市場変数と見通し

  • SWOT分析
    • 強み
    • 弱み
    • 機会
    • 脅威
  • PESTEL分析
    • 政治情勢
    • 経済情勢
    • 社会情勢
    • 技術情勢
    • 環境情勢
    • 法的情勢
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入者の脅威
    • 競合企業間の敵対関係
  • ヒートマップ分析

第6章 世界のパーキンソン病治療薬市場：年齢層別、2019年～2032年（100万米ドル）

  • 50歳以下
  • 50歳以上

第7章 世界のパーキンソン病治療薬市場：薬物クラス別、2019年～2032年（100万米ドル）

  • デカルボキシラーゼ阻害剤
  • ドーパミン作動薬
  • COMT阻害剤
  • MAO-B阻害剤
  • その他

第8章 世界のパーキンソン病治療薬市場：投与経路別、2019年～2032年（100万米ドル）

  • 注射
  • 経口
  • 経皮

第9章 世界のパーキンソン病治療薬市場：地域別、2019年～2032年（100万米ドル）

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • サウジアラビア王国
    • アラブ首長国連邦
    • その他の中東・アフリカ

第10章 企業プロファイル

  • AbbVie Inc.
    • 企業概要
    • 財務見通し
    • 製品概要
    • 最近の開発
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc., C.H.
  • Boehringer Sohn Ko. KG
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd
  • Gentech Healthcare
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Square group
  • Sun Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Torrent Group
  • UCB
  • Viatris Inc.
目次
Product Code: PHAR2209

Global Parkinson's Disease Drugs Market Overview:

According to SPER Market Research, the Global Parkinson's Disease Drugs Market is estimated to reach USD 10.93 billion by 2032 with a CAGR of 6.5%.

Parkinson's Disease, also known as idiopathic Parkinsonism, is a neurodegenerative disease. It is a progressive disease that affects both the neurological system and the bodily components controlled by the nervous system. Dopamine is produced in the substantia nigra region of the brain. Dopamine levels decrease in Parkinson's Disease as substantial cells in the brain begin to die. Parkinson's Disease may be caused by environmental or genetic factors. Those with an affected family member are at a higher risk of contracting the disease, as certain genes are known to be inheritable risk factors. Tremors, slowed movement, rigid muscles, impaired posture and balance, speech changes, and other symptoms are common. Non-motor symptoms usually appear gradually, and as the disease progresses, they become more common. Age is the most important risk factor, but other factors such as environment and heredity also play a role.

Significant factors driving market growth include a large patient pool and an increasing rate of diagnosis. According to the Parkinson's Disease Foundation, nearly 10 million people worldwide suffer from this disorder. This disorder is most common in developed countries, with nearly 60,000 new cases reported each year in the United States. Demand for Parkinson's Disease drugs is expected to rise globally during the forecast period, owing to an increase in the geriatric population, which drives the market growth. Furthermore, increases in R&D investments by key players in Parkinson's Disease drugs, as well as an increase in the geriatric population, are some factors driving the growth of the Parkinson's Disease drugs industry. The COMT inhibitors are expected to grow at the fastest rate during the forecast period due to advantages such as long-lasting enzyme inhibition, reduced adverse effects of drugs, and lower levodopa dose. The oral route of administration is expected to grow the fastest during the forecast period, owing to more pre-determined doses, convenience, and patient self-administration. The over-50 age group is expected to continue this trend during the forecast period. This is due to an aging population, as age is a risk factor for Parkinson's Disease, which increases the over-50 age group. However, the side effects of Parkinson's Disease drugs may limit the market growth.

Impact of COVID-19 on the Global Parkinson's Disease Drugs Market

The global Parkinson's Disease drugs market fell in 2020 as a result of the global economic recession caused by COVID-19. However, the market will recover in the forecast period as a result of increased Parkinson's Disease drug adoption and an increase in Parkinson's Disease drug R&D pipeline products.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Age group, By Drug Class, By Route of administration

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered AbbVie Inc., Amneal Pharmaceuticals, Inc., Biogen Inc., C.H., Boehringer Sohn Ko. KG, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Gentech Healthcare, GlaxoSmithKline Plc, Intas Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., Square group, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Torrent Group, UCB, Viatris Inc.

Global Parkinson's Disease Drugs Market Segmentation:

By Age Group: Based on the Age Group, Global Parkinson's Disease Drugs Market is segmented as; 50 or below 50 (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Above 50 years (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region).

By Drug Class: Based on the Drug Class, Global Parkinson's Disease Drugs Market is segmented as; Decarboxylase Inhibitors {Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region, Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel (Hospital Pharmacies Market size and forecast, by region, Drug stores and Retail Pharmacies Market size and forecast, by region, Online Providers Market size and forecast, by region), Dopamine Agonists (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), COMT Inhibitors (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), MAO-B Inhibitors (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Others.

By Route of Administration: Based on the ROA, Global Parkinson's Disease Drugs Market is segmented as; Injectable (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Oral (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Transdermal (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region).

By Region: During the forecast period, North America is expected to dominate the Parkinson's Disease drugs market, accounting for the largest share. This is due to factors such as the presence of key players in the region and the availability of diagnostic laboratories. Furthermore, high-quality healthcare in the United States is expected to drive the growth of the North American market.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Parkinson's Disease Drugs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Parkinson's Disease Drugs Market, By Age Group, 2019-2032 (USD Million)

  • 6.1. 50 or below 50
    • 6.1.1. Key market trends, growth factors and opportunities
    • 6.1.2. Market size and forecast
    • 6.1.3. Market analysis by Region
  • 6.2. Above 50 years
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast
    • 6.2.3. Market analysis by Region

7. Global Parkinson's Disease Drugs Market, By Drug Class, 2019-2032 (USD Million)

  • 7.1. Decarboxylase Inhibitors
    • 7.1.1. Key market trends, growth factors and opportunities
    • 7.1.2. Market size and forecast
    • 7.1.3. Market analysis by Region
    • 7.1.4. Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
      • 7.1.4.1 Hospital Pharmacies Market size and forecast, by region
      • 7.1.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
      • 7.1.4.3 Online Providers Market size and forecast, by region
  • 7.2. Dopamine Agonists
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast
    • 7.2.3. Market analysis by Region
  • 7.3. COMT Inhibitors
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast
    • 7.3.3. Market analysis by Region
  • 7.4. MAO-B Inhibitors
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast
    • 7.4.3. Market analysis by Region
  • 7.5. Others
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast
    • 7.5.3. Market analysis by Region

8. Global Parkinson's Disease Drugs Market, By Route of Administration, 2019-2032 (USD Million)

  • 8.1. Injectable
    • 8.1.1. Key market trends, growth factors and opportunities
    • 8.1.2. Market size and forecast
    • 8.1.3. Market analysis by Region
  • 8.2. Oral
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast
    • 8.2.3. Market analysis by Region
  • 8.3. Transdermal
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast
    • 8.3.3. Market analysis by Region

9. Global Parkinson's Disease Drugs Market, By Region, 2019-2032 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AbbVie Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Amneal Pharmaceuticals, Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Biogen Inc., C.H.
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Boehringer Sohn Ko. KG
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Eli Lilly and Company
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4 Recent developments
  • 10.6. F.Hoffmann-La Roche Ltd.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Gentech Healthcare
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. GlaxoSmithKline Plc
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Intas Pharmaceuticals Limited
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Merck & Co., Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11 Novartis AG
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Orion Corporation
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Pfizer Inc.
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Square group
    • 10.14.1. Company detail
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Sun Pharmaceutical Industries
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Teva Pharmaceuticals
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent development
  • 10.17. Torrent Group
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent development
  • 10.18. UCB
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent development
  • 10.19. Viatris Inc.
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent development